An Act to renumber and amend 632.895 (6); to amend 609.83 and 632.895 (6) (title); to create 632.895 (6) (b) of the statutes; Relating to: cost-sharing cap on insulin.
SB901 would place a statutory cap on out-of-pocket cost sharing for insulin under Wisconsin disability insurance policies and governmental self-insured health plans that cover insulin and already impose cost sharing on prescription drugs. The bill limits the amount a covered person may be charged for insulin to no more than $35 for a one-month supply. It also defines “cost sharing” to include deductibles, copayments, and coinsurance, and it allows plans to charge less than $35 or no cost sharing at all.
The bill amends existing diabetes coverage law in s. 632.895 (6) and updates the related title to expressly include insulin. Current law requires coverage for diabetes-related equipment, supplies, insulin, and self-management education, but generally allows those benefits to be subject to the same exclusions, limitations, deductibles, and coinsurance as other covered services. SB901 creates an exception to that rule for insulin by overriding the usual cost-sharing treatment and applying the new cap instead. It also cross-references the new insulin cap in the statute governing certain health plan types, including limited service health organizations, preferred provider plans, and defined network plans.
The bill would affect both fully insured disability policies and self-insured health plans, broadening the reach of the insulin cap beyond traditional insurance products. Because the bill may be treated as a health insurance mandate, it could trigger a required social and financial impact report under Wisconsin law. The bill would take effect on the first day of the fourth month after publication if enacted.
The overall sentiment reflected by the bill’s introduction is supportive of lowering insulin costs and reducing financial barriers for people who rely on insulin. However, there is no recorded committee transcript or vote history in the provided materials, and the bill ultimately failed to pass pursuant to Senate Joint Resolution 1. That means there is no documented floor or committee debate in the supplied record to show explicit support or opposition arguments.
The main point of contention inherent in the bill is the insurance mandate itself: it would require insurers and self-insured plans to alter standard cost-sharing structures for a specific prescription drug. Potential concerns would likely center on premium impacts, administrative changes for health plans, and whether the state should regulate insulin pricing through coverage rules. On the other hand, supporters would likely emphasize affordability, access, and the importance of predictable insulin costs for people with diabetes.
SB901 would amend Wisconsin insurance statutes to create a new insulin-specific cost-sharing limit, capping out-of-pocket charges at $35 per one-month supply for covered insulin under disability insurance policies and self-insured health plans. It would override the general rule in current diabetes coverage law that allows insulin and other diabetes-related benefits to be subject to the same deductibles, coinsurance, and exclusions as other covered services. The bill would also update related statutory references so that certain health plan types are expressly subject to the new insulin cap.
The bill appears to be driven by a pro-affordability, pro-access approach to diabetes care, with the introduction by a bipartisan group of senators and representatives suggesting broad interest in limiting insulin costs. At the same time, the absence of committee discussion or recorded votes in the provided materials means there is no direct evidence of debate outcomes or negotiated compromise. The bill’s failure to pass indicates that, despite likely support for the policy goal, it did not advance through the legislative process.
The central contention is whether Wisconsin should impose a mandated cap on insulin cost sharing for private and self-insured health coverage. Supporters would likely argue that insulin is a medically necessary, life-sustaining drug and that high out-of-pocket costs create barriers to treatment. Opponents or skeptics would likely focus on the bill’s status as a health insurance mandate, possible premium increases, and the broader policy question of whether the state should intervene in prescription drug cost-sharing rules. Because no committee transcript is provided, these positions are inferred from the bill’s structure rather than from recorded debate.